Rationale: Platelets contain abundant thymidine phosphorylase (TYMP), which is highly expressed in diseases with high risk of thrombosis, such as atherosclerosis and type II diabetes mellitus. Objective: To test the hypothesis that TYMP participates in platelet signaling and promotes thrombosis. Methods and Results: By using a ferric chloride (FeCl 3 )-induced carotid artery injury thrombosis model, we found time to blood flow cessation was significantly prolonged in Tymp −/− and Tymp +/− mice compared with wildtype mice. Bone marrow transplantation and platelet transfusion studies demonstrated that platelet TYMP was responsible for the antithrombotic phenomenon in the TYMP-deficient mice. Collagen-, collagen-related peptide-, adenosine diphosphate-, or thrombin-induced platelet aggregation were significantly attenuated in Tymp +/− and Tymp −/− platelets, and in wild type or human platelets pretreated with TYMP inhibitor KIN59. Tymp deficiency also significantly decreased agonist-induced P-selectin expression. TYMP contains an N-terminal SH3 domainbinding proline-rich motif and forms a complex with the tyrosine kinases Lyn, Fyn, and Yes in platelets. TYMPassociated Lyn was inactive in resting platelets, and TYMP trapped and diminished active Lyn after collagen stimulation. Tymp/Lyn double haploinsufficiency diminished the antithrombotic phenotype of Tymp +/− mice. TYMP deletion or inhibition of TYMP with KIN59 dramatically increased platelet-endothelial cell adhesion molecule 1 tyrosine phosphorylation and diminished collagen-related peptide-or collagen-induced AKT phosphorylation. In vivo administration of KIN59 significantly inhibited FeCl 3 -induced carotid artery thrombosis without affecting hemostasis.
T hrombotic events are a major cause of morbidity and mortality in developed nations and remain an important area for new therapeutic discoveries. Inappropriate or uncontrolled platelet activation at site of vascular injury is an important pathogenic component of thrombosis, which causes myocardial infarction or stroke. Therefore, understanding the complex signaling pathways involved in promoting and inhibiting platelet activity remains high priority.
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Human platelets contain >4000 proteins, 1 and for the most part the functions of these proteins are not known with certainty. Thymidine phosphorylase (TYMP) was initially purified from human platelets, and each human platelet contains ≈116 000 copies of TYMP. 1 TYMP reversibly converts thymidine to thymine and 2-deoxy-d-ribose-1-phosphate (2DDRP), 2 and the latter sugar is further degraded to 2-deoxy-d-ribose (2DDR). TYMP thus maintains the nuclear pool of these molecules and contributes to the nucleotide salvage pathway. In 1987, a potent angiogenic protein, platelet-derived endothelial cell growth factor, was purified from human platelets 3 and was later shown to be identical to human TYMP. 4 The angiogenic effect of TYMP 5 is supported by observations that TYMP expression in tumors is associated with enhanced angiogenesis. 6, 7 The angiogenic effect of TYMP is thought to be mediated by its mobilizing effect on endothelial cells, but the actual mechanism(s) remain undefined. 6, 8 We have found that direct injection of a plasmid vector encoding human TYMP into ischemic canine myocardium or rabbit hindlimb promotes angiogenesis in cardiac and skeletal muscle 5, 9, 10 and improves myocardial function and prevents hindlimb necrosis. We also found that TYMP inhibited vascular smooth muscle cell proliferation and migration. [11] [12] [13] The inhibitory role of TYMP on vascular smooth muscle cell is partly mediated by regulating the phosphorylation of Lyn, 12 an important nonreceptor tyrosine kinase of the Src family. TYMP is also expressed in monocytes/macrophages and stromal cells, suggesting that it may have additional roles in the circulatory systems. Interestingly, although TYMP was initially isolated from platelets, its role in platelet physiology is largely unexplored.
In this study, we examined the hypothesis that TYMP participates in platelet activation and promotes thrombosis. To this end, we used a combination of ex vivo studies of human platelets treated with a pharmacological TYMP inhibitor or platelets purified from mice with TYMP deficiency along with in vivo models of arterial thrombosis in genetically modified mice or TYMP inhibitor-treated mice. These approaches show that TYMP contributes to platelet activation and promotes thrombosis in a platelet-dependent manner. We also defined a signaling pathway in which TYMP interacts with Lyn, Fyn, and Yes in platelets to regulate their function.
Methods
All animal uses have been approved by the Institutional Animal Care and Use Committee of The Cleveland Clinic. Methods are available in the Online Data Supplement.
Results

Tymp Deficiency in Mice is Antithrombotic and Platelets Account for the Prothrombotic Role of TYMP
To examine whether TYMP affects thrombosis, 8-to 12-weekold male Tymp +/− and Tymp −/− mice were subjected to the FeCl 3 -induced carotid artery injury thrombosis model. 14 Male wild-type (WT) mice were used as controls. Figure 1A and Online Movies I to III show representative thrombi formation in the 3 strains over time. Thrombi were confirmed immediately after removing the 7.5% FeCl 3 solution saturated filter paper (1 minute in Figure 1A ), and no gross differences were observed among the 3 groups. As usual, parts of the initially formed thrombi were washed away by blood flow in all groups ( Figure 1A , 2 minutes). Thrombi started to enlarge 3 to 4 minutes after removing the filter paper, and these later thrombi were stable and not washed away. The thrombi in WT mice formed faster than those in Tymp +/− or Tymp −/− mice. Cessation of blood flow was seen in all WT mice (n=9) with an average vessel occlusion time of 11.4 minutes ( Figure 1B-1D ). Only 3 of the 9 Tymp +/− mice and 4 of the 9 Tymp −/− mice showed flow cessation within the 30 minutes of observation with average occlusion times >20 minutes ( Figure 1B-1E ). Occlusion times were significantly different between WT and mice with any defect in Tymp, but were not different when comparing Tymp −/− to Tymp +/− mice. These data show TYMP contributes to thrombus formation and suggest that even partial insufficiency of TYMP is enough to provide antithrombotic benefit.
Because TYMP deficiency has been associated with mitochondrial dysfunction in nucleated human cells, we assessed platelet mitochondrial function by MTT assay. We found no differences in platelet mitochondrial function among the 3 strains (Online Figure IA) , which was identical to the original description in this mouse strain. 15 TYMP deletion also did not affect circulating platelet counts (Online Figure IB) . TYMP and its ultimate product 2DDR induce integrin β1 and β3 activation or expression in endothelial cells. 16, 17 We found that TYMP haplodeficiency or completely deletion did not change the expression of integrin β1 and β3 in platelets; von Willebrand factor levels were also comparable among the 3 strains (Online Figure IC) .
Vera et al 18 reported that activated platelets secrete 2DDRP, which acts as a cooperative agonist and potentiates platelet activation in response to thrombin. To examine the potential that 2DDRP is low and thus induces antithrombotic phenotype in the TYMP-deficient mice, murine plasma obtained by ultracentrifugation of platelet poor plasma was analyzed by liquid chromatography online tandem mass spectrometry. As shown in Online Figure ID , plasma 2DDRP was similar among the WT, Tymp +/− , and Tymp −/− mice, suggesting that 2DDRP levels are not responsible for the observed phenotype in the Tymp +/− and Tymp −/− mice.
We thus performed bone marrow transplant using Tymp −/− and WT mice to determine the cellular basis of the TYMP-mediated prothrombotic effect. Recipient mice were exposed to 10.5 Gy of external beam irradiation and then infused with 2×10 6 donor bone marrow cells by jugular vein injection 4 hours after irradiation. Surviving chimeric mice were subjected to FeCl 3induced carotid artery thrombosis 4 weeks later. The time necessary to form occlusive thrombi was significantly prolonged in WT mice that received Tymp −/− bone marrow when compared with WT mice that received WT marrow ( Figure 1F ); Tymp −/− mice that received WT bone marrow displayed significantly shorter arterial occlusion times when compared with Tymp −/− mice that received Tymp −/− marrow. These data demonstrated that repleting TYMP in circulating cells reverses the antithrombotic effect of systemic TYMP deletion and that TYMP in cells of the vessel wall is not involved in the observed phenotype.
Erythrocytes do not express TYMP so we next distinguished the effect of platelet versus leukocyte TYMP on thrombosis. To do this, platelet transfusion experiments were performed in mice rendered severely thrombocytopenic by irradiation, which decreased platelet counts to ≈5% of normal after 5 to 6 days. [19] [20] [21] Donor platelets were isolated from Tymp +/− , Tymp −/− , or WT mice, labeled with rhodamine 6G, and then transfused into the thrombocytopenic mouse via jugular vein injection 10 minutes before FeCl 3 injury. Each mouse received 10 9 platelets, which resulted in a final circulating platelet concentration of 6×10 11 L±1.1×10 11 /L in ≈25 g mice (n=3). Reconstitution of Tymp +/− platelets in Tymp +/− recipient mice resulted in similar occlusion times as nonirradiated Tymp +/− mice. However, thrombocytopenic Tymp +/− mice receiving WT platelets showed an average flow cessation time of 11 minutes, which was significantly shorter than the time to occlusion in thrombocytopenic Tymp +/− mice received Tymp +/− platelets. Similarly, WT recipients transfused with Tymp −/− platelets showed significantly prolonged blood flow cessation time when compared with WT or Tymp −/− animals reconstituted with WT platelets ( Figure 1G ). These studies demonstrate that platelet TYMP is an important determinant of the antithrombotic phenotype of the Tymp-deficient animals.
TYMP is Involved in Platelet Activation
To clarify how TYMP affects thrombosis, we examined agonistinduced platelet aggregation and granule secretion. As shown in Figure 2A , Tymp deletion or haploinsufficiency significantly attenuated ADP-induced platelet aggregation in platelet-rich plasma; the maximum extent of aggregation was reduced ≈33% compared with WT platelets. Tymp deletion nearly abolished platelet aggregation in response to 1 μg/mL collagen ( Figure 2B ). Tymp haploinsufficiency also significantly blunted platelet aggregation in response to the low-dose collagen, but to a lesser extent than homozygous deletion. We further demonstrated that TYMP deletion significantly decreased thrombin and collagenrelated peptide (CRP)-induced aggregation of washed platelet ( Figure 2C and 2D). All platelet-activating receptors ultimately trigger platelet α-granule release, resulting in P-selectin translocation to the platelet surface. As shown in Figure 2E , P-selectin expression detected by flow cytometry was significantly attenuated in Tymp-deficient platelets in response to collagen (1 μg/ mL), ADP (2.5 μmol/L), thrombin (0.05 U/mL), or CRP (0.5 μg/mL). Tymp deletion also significantly attenuated high-dose agonist-induced platelet activation (Online Figure II) . These data suggest that TYMP participates in platelet signaling and activation in response to multiple receptors.
TYMP Forms a Complex With Src Family Kinases in Platelets
We previously found that TYMP overexpression induced constitutive phosphorylation of Lyn kinase in vascular smooth muscle cell. 12 Lyn is a major Src family kinases (SFK) in human and mouse platelets and plays important and complex roles in platelet activation. 22 All SFKs contain an SH3 domain that serves as a site for protein interactions by binding to prolinerich peptide sequences in its binding partners. 23 We analyzed the sequence of human TYMP and discovered a consensus SH3-binding sequence APPAP 24 at the N terminus of TYMP F, wild-type (WT) and Tymp −/− recipient mice were exposed to 10.5 Gy of external beam irradiation, and then received bone marrow (BM) transplantation as indicated. The successful BM engrafted mice were subjected to 7.5% FeCl 3 -induced injury on carotid arteries 4 weeks later (n=4-6). G, Tymp +/− , Tymp −/− or WT recipient mice were exposed to 11 Gy of irradiation and allowed to live for 5 days to induce serious thrombocytopenia. Donor platelets isolated from WT, Tymp +/− or Tymp −/− mice were labeled with Rhodamine 6G, and total 10 9 platelets in 200 μL saline were transfused into the recipient mouse via jugular vein injection. The mice were then subjected to 7.5% FeCl 3induced carotid artery injury. n=5 in each group. December 5, 2014
( Figure 3A ), which is highly conserved in different primate species. Murine TYMP also contains a core-binding motif PxxP, 25 which is also highly preserved in other orders. These findings suggest that TYMP could directly influence platelet signaling via SFKs or other SH3 domain containing signaling proteins.
To test this hypothesis, we first examined whether TYMP interacts with SFKs in platelets. Resting human platelet lysates were immunoprecipitated with specific monoclonal antibodies to TYMP and then the precipitates were assessed for immunoblotting the SFKs, including Src, Lyn, Fyn, and Yes. Normal mouse or rabbit IgG did not pull down any Src, Lyn, Fyn, or Yes, nor TYMP (Online Figure III and not shown). Anti-TYMP precipitates, however, contained Lyn, Fyn, and Yes, but not Src ( Figure 3B and 3C). Conversely, anti-Lyn, Fyn, and Yes precipitates also contained TYMP ( Figure 3D ). These findings were reproduced using platelets from 4 different donors and were also confirmed using mouse platelets (data not shown).
Inhibition of TYMP Reduces TYMP/Lyn Association and Glycoprotein VI-Mediated Lyn Activation
Insights gained from structure studies suggest that substrate (or inhibitor) binding induces a conformational change in TYMP, which is essential for its phosphorylase action. 26 Conformation changes are also essential for protein-protein interaction. TYMP metabolites, including thymidine, 2DDR, and 2DDRP did not affect agonist-induced platelet aggregation (Online Figure IV) , suggesting that the phosphate and the nucleoside-binding sites of TYMP are not responsible for its effect on platelet function. We thus examined whether another element of the active site of human TYMP, aspartic acid-203 27 , affected its association with SFKs using a potent Asp203binding TYMP inhibitor, KIN59 28, 29 . As shown in Figure 4A , collagen stimulation significantly increased the amount of TYMP that coprecipitated with Lyn. Inhibition of TYMP with KIN59 significantly decreased the amount of Lyn that coprecipitated with TYMP ( Figure 4A and 4B) . Immunoblotting of the TYMP precipitates with antibodies specific for phosphorylated Lyn showed that the TYMP-associated Lyn ( Figure 4B ) was phosphorylated at Y507, an inactive status in resting platelets. On collagen stimulation, TYMP-associated Lyn was rapidly phosphorylated at Y396. However, activity of the TYMP associated Lyn (detected by phosphorylation at Y396) was only higher at the initial phase (within 1 minute), but was significantly decreased over time (3 minutes) . This phenomenon was dramatically blocked by KIN59, suggesting that TYMP may act by trapping and diminishing active Lyn. Lyn phosphorylates platelet-endothelial cell adhesion molecule 1 (PECAM1, CD31) within its immunoreceptor tyrosine-based inhibitory motif that inhibits platelet activation in response to collagen stimulation. 30 In the presence of the TYMP inhibitor KIN59, we found that inhibition of TYMP activity significantly increased tyrosine phosphorylated PECAM1 ( Figure 4C ), potentially from Lyn release. It is known that activated PECAM1 recruits and activates tyrosine phosphatase SHP-2, which subsequently binds to phosphoinositol 3-kinase and diminishes phosphoinositol 3-kinase signaling. 31 As a marker of phosphoinositol 3-kinase signaling pathway activation, we assessed AKT phosphorylation, and found KIN59 treatment dramatically inhibited collagen-induced AKT phosphorylation ( Figure 4C ). To confirm this finding, we pooled platelets harvested from 10 to 12 mice, divided them into 3 groups and then stimulated the platelets with CRP for indicated times. As shown in Figure 4D , in comparison with WT platelets, CRP-induced AKT phosphorylation was dramatically reduced in Tymp −/− and Lyn −/− platelets. Tyrosine phosphorylated PECAM1 was significantly increased in Tymp −/− platelets in response to CRP stimulation, but not in WT and Lyn −/− platelets. These data suggest that TYMP and Lyn form an association that regulates Lyn function and subsequently affects glycoprotein VI signaling-mediated platelet activation.
Lyn Deficiency Reverses the Antithrombotic Phenotype of Tymp-Deficient Mice
Having shown that TYMP interacts with SFKs and regulates SFKs activity in platelets, we hypothesized that deletion of SFK would diminish the antithrombotic phenotype of Tymp deficiency. Yes is not expressed in mouse platelets. Fyn only plays a minor role in mediating glycoprotein VI signaling, 22 which plays critical roles in response to vascular injury 32 including the FeCl 3 -induced arterial thrombosis model. 33 By platelet transfusion experiments, we found blocking WT platelets with glycoprotein VI antibody significantly prolonged thrombosis time in the 7.5% FeCl 3 injury-induced carotid artery thrombosis model ( Figure 5A ). Transfusion of Fyn null platelets to the thrombocytopenic WT mice did not affect thrombosis time when compared WT mice received WT platelets (data not shown), supporting that platelet Fyn plays a minor role in this model. We thus focused on the effect of Lyn and crossed Tymp −/− mice with Lyn −/− animals 34 to generate Tymp +/− ; Lyn +/− mice. Consistent with our hypothesis, Lyn haploinsufficiency dramatically diminished the prolonged thrombosis time displayed by the Tymp +/− and Tymp −/− mice to the levels of WT and Lyn −/− mice ( Figure 5B ).
KIN59 Inhibits Platelet Aggregation In Vitro and Has an Antithrombotic Effect In Vivo Without Affecting Hemostasis
Having shown that inhibition of TYMP with KIN59 affected activity of platelet signaling molecules, we next examined whether inhibition of TYMP with KIN59 affects platelet activation. KIN59 reversibly and in a dose-dependent fashion inhibited collagen-induced platelet aggregation (Online Figure V) . Figure 6A shows cumulative data for different concentrations of KIN59 on different doses of collagen-induced platelet aggregation. These studies demonstrate that inhibition of TYMP activity significantly inhibited platelet aggregation in response to collagen stimulation. Treatment of WT platelets in platelet-rich plasma with KIN59 also dramatically inhibited aggregation in response to 1 μg/mL collagen ( Figure 6B ), replicating the pattern seen with Tymp −/− platelets. KIN59 also significantly inhibited aggregation induced by ADP, thrombin, and CRP (not shown).
Given that TYMP plays an important role in platelet activation in response to stimulation by any of examined agonists, we determined whether pharmacological inhibition of TYMP activity affects thrombosis in vivo. KIN59, 30 mg/kg per day, has previously been delivered in vivo to mice and shown to inhibit TYMP-induced angiogenesis 35, 36 without producing obvious side effects. We treated WT and Tymp −/− mice with intraperitoneal injection of KIN59 (30 mg/kg/d) for 3 days, and then subjected the mice to FeCl 3 -induced carotid artery injury. Vehicle treatment did not affect carotid artery occlusion times when compared with the untreated WT mice; KIN59 administration, however, significantly prolonged the time to form occlusive thrombus in the WT mice ( Figure 6C ; Online A, A consensus SH3-binding sequence APPAP was found in different primate TYMPs; and a core-binding motif PxxP was also found in murine and other orders. B-D, Immunoprecipitationimmunoblotting assays were performed using indicated antibodies to determine the interaction of TYMP and Src family kinases, including Lyn, Fyn, Src, and Yes in human platelets. December 5, 2014
Movies IV and V). KIN59 did not further prolong blood cessation time in the Tymp −/− mice (not shown), suggesting that the effect is TYMP dependent.
Hemorrhagic complications are associated with all currently available antiplatelet and anticoagulation therapies. We assessed activated partial thromboplastin time and tail bleeding time to determine whether TYMP deficiency affects hemostasis. Activated partial thromboplastin time was not significantly different among the WT, Tymp +/− , and Tymp −/− mice ( Figure 6D ). Tymp haploinsufficiency also did not influence bleeding time Platelets lysates were analyzed by immunoprecipitation and immunoblotting assays using indicated antibodies. Bar graph shows Lyn activity from 3 independent experiments. *P<0.05 vs corresponding times of KIN59 treatments. C, Human platelets treated as in panel A were analyzed by Western blot using indicated antibodies. Bar graph represents 3 independent experiments. D, Mouse platelets pooled from 10 to 12 mice were divided into 3 groups and stimulated with collagen-related peptide as indicated. Platelet lysates were used for immunoprecipitation and immunoblotting assays using indicated antibodies. Bar graph shows the ratio of phosphorylated AKT and PECAM1 to their total proteins.
( Figure 6E ). Bleeding times were prolonged ≈2-fold in Tymp −/− mice; however, this level of increase was not associated with any increase in surgical mortality or in observable bleeding at the surgical site. KIN59 treatment for 3 days also did not affect bleeding time ( Figure 6E ), as well as plasma 2DDRP (Online Figure VI) when compared with the mice received vehicle injection. These data suggest that TYMP may play a role in normal hemostasis, but that haploinsufficiency or significant enzymatic inhibition is not sufficient to cause a hemostatic defect.
Discussion
In this study, we demonstrated for the first time that TYMP promotes thrombosis by regulating platelet activation. We found that (1) TYMP deletion or haploinsufficiency in platelets significantly prolonged thrombotic occlusion times in response to FeCl 3 -induced carotid artery injury without affecting hemostasis; (2) TYMP deletion or haploinsufficiency significantly attenuated ADP-, collagen-, CRP-, and thrombin-induced platelet aggregation and α-granule release; (3) in response to platelet agonists, TYMP interacts with Lyn, Fyn, and Yes and modulates activity of Lyn and its downstream signaling molecules, such as PECAM1 and AKT; (4) Lyn haploinsufficiency diminished the phenotype found in the Tymp +/− mice; and (5) pharmacological inhibition of TYMP activity reduced agonist-induced human and murine platelet aggregation in vitro and prolonged murine thrombosis times in vivo without affecting hemostasis. This study indicates that targeting TYMP might be a novel antiplatelet or antithrombosis therapy.
TYMP has been found in atherosclerotic plaques, 37,38 serum of patients with type II diabetes mellitus 39 and cancer. 40 All these diseases have high risk of thrombosis, suggesting that TYMP may play a role in these diseases-associated thrombophilia. This hypothesis is supported by 1 study reported a Figure 6 . Pharmacological inhibition of TYMP activity inhibits platelet aggregation and thrombosis without affecting hemostasis. A, The effect of different concentrations of KIN59 on different doses of collagen-induced human platelet aggregation. n=6 to 9. B, The effect of KIN59 (250 μmol/L) on murine platelet aggregation in response to 1 μg/mL collagen stimulation, n=6. C, The effect of KIN59 on thrombosis was assessed on eight weeks old wild-type (WT) mice that were treated with KIN59 (30 mg/kg/d) for 3 days. The mice were then subjected to 7.5% FeCl 3 -induced carotid artery thrombosis model, n=6. D, activated partial thromboplastin time (aPTT) assay was performed using platelet-poor-plasma from 5 different mice. E, Tail bleeding time was assessed in anesthetized WT, Tymp +/− and Tymp −/− mice by cutting 1 cm of tail from the tip, or in WT mice received KIN59 (30 mg/kg/d) or vehicle treatment for 3 days. n=6. December 5, 2014 decade ago in which increased expression of TYMP in human hepatocellular carcinomas was correlated with high incidence of portal vein thrombosis. 41 This hypothesis is also supported by a recent study, in which perfusion of erythrocyte-encapsulated TYMP to mice resulted in thrombi in the lungs. 42 Interestingly, Aspirin, an antiplatelet drug, inhibits TYMP production in a human monocyte cell line, THP1 cells, 43 suggesting that Aspirin may also inhibit TYMP production in platelet and thus results in the antithrombotic effect. We found that TYMP deficiency did not affect expression of glycoprotein Ib, glycoprotein VI (not shown), von Willebrand Factor or integrin β 1 and β 3 expression in platelets nor was the number of circulating platelets or their mitochondrial function affected by the loss of TYMP. These observations exclude platelet quantity and quality as the source of defective platelet action in the Tymp haploinsufficient or null mice. Activated platelets secrete 2DDRP, which can act as a cooperative agonist and potentiates platelet activation. 18 We found no difference in plasma 2DDRP between Tymp deficient and WT mice or between KIN59 and vehicle-treated mice by liquid chromatography online tandem mass spectrometry. Mouse uridine phosphorylase also catalyzes thymidine metabolism. 15 Because uridine phosphorylase is not expressed in platelets 1 and thymidine levels were not significantly higher in the Tymp −/− mice, 15 we presume 2DDRP in platelets of the Tymp deficient or null mice should not be high. Indeed, pretreatment of platelets with thymidine, 2DDRP, and 2DDR did not alter ADP and collagen-induced platelet aggregation (Online Figure IV) . We thus exclude levels of the TYMP metabolites as the source of the antithrombotic phenotype in the Tymp-deficient mice.
By in vivo thrombosis studies in chimeric mice generated by bone marrow transplant or thrombocytopenic mice reconstituted with WT or Tymp haploinsufficient platelets, we demonstrated that platelet TYMP plays a role in platelet activation and thrombosis, suggesting that TYMP participates in platelet signaling pathway to regulate platelet activation. By analyzing the amino acid sequence of TYMP proteins, we found the N terminus of most mammalian TYMPs contain an SH3 domain-binding proline-rich motif (APPAP in primate) or a core-binding motif (PxxP, in rodents or other species). 25 This finding suggests a molecular mechanism enabling TYMP to participate in signaling by directly binding to SH3 domain containing proteins, such as SFKs. We found that TYMP overexpression induced constitutive Lyn tyrosine phosphorylation in vascular smooth muscle cell. 12 Here, we demonstrate that TYMP forms a complex with Fyn, Lyn, and Yes in human and murine platelets. We found that TYMP associates with Lyn, and that this depends on Asp203mediated TYMP conformation formation. Furthermore, association of Lyn with TYMP rapidly diminished Lyn phosphorylation at Y396 residue induced by collagen suggesting Lyn activity was inhibited. These data suggest that TYMP acts to sequester active Lyn to decrease Lyn function. Thus, loss of TYMP increases Lyn inhibition of platelet activation.
SFKs share individual and overlapping roles in platelet activation. 22 Fyn mainly acts as a stimulation factor; however, Lyn modulates both activation and inhibition of platelet. 44 Lyn and Fyn are constitutively associated with the cytoplasmic domain of glycoprotein VI, 45, 46 and Lyn-and Fyn-mediated phosphorylation of the F C receptor γ chain immunoreceptor tyrosine-based activation motif domain promotes glycoprotein VI-mediated platelet activation. In vitro studies thus showed that Lyn mediates a rapid response to collagen stimulation, especially obvious at low collagen concentrations, 46, 47 and a delayed response of platelets to low doses of collagen-induced aggregation was found in Lyn null platelets. 22 We also showed that Lyn functions downstream of CD36 in activating platelets through danger-associated molecular patterns, such as oxidized LDL. 20 Lyn, however, also inhibits collagen-induced platelet activation via phosphorylation of PECAM1 immunoreceptor tyrosine-based inhibitory domain 48, 49 and Lyn-deficient platelets are thus hyper-responsive to collagen stimulation. 49 By examining PECAM1 phosphorylation, we found Tymp deletion or inhibition of its activity significantly increased platelet PECAM1 tyrosine phosphorylation in vitro ( Figure 4C and 4D) . In combination with the fact that TYMP diminishes Lyn phosphorylation at Y396, our data suggest that TYMP attenuates Lyn-mediated PECAM1/immunoreceptor tyrosine-based inhibitory phosphorylation in platelets. TYMP deficiency thus increases Lyn/PECAM1-mediated platelet inhibition and inhibits thrombosis. Our in vivo data suggest this concept as Lyn −/− mice showed a modest acceleration of thrombosis times ( Figure 5B , Online Figure VII and Movie VI), and haploinsufficiency of Lyn significantly diminished the antithrombotic phenotype found in Tymp +/− mice. Therefore, our studies indicate that TYMP participates in glycoprotein VI signaling, and regulates Lyn, PECAM1, and phosphoinositol 3-kinase/AKT signaling and platelet function (Figure 7 ). We also found TYMP influences ADP and thrombin-mediated platelet activation, suggesting a potential role of TYMP in G-protein-coupled receptor signaling. This phenomenon may also because of the effect of TYMP on Lyn activation as Lyn also mediates thrombin-induced 50 and ADP 51 -induced platelet activation.
A human rare autosomal recessive syndrome known as mitochondrial neurogastrointestinal encephalomyopathy has been associated with TYMP loss of function. Patients with this disorder generally die in early adulthood, although at this point no bleeding or thrombotic diathesis has been described. Heterozygous carriers have no discernible phenotype. 52 Indeed, no clinical symptoms of mitochondrial neurogastrointestinal encephalomyopathy were present in the Tymp −/− mice. 15 Tymp −/− mice generated by a different group also did not show any symptoms of mitochondrial neurogastrointestinal encephalomyopathy. 53 A TYMP inhibitor known as Tipiracil is a component of an experimental anticancer drug TAS-102 and has been used in phase I, II, and III clinical trials. Available data from these studies did not show any bleeding problems or any symptoms similar to the mitochondrial neurogastrointestinal encephalomyopathy. By examination of activated partial thromboplastin time and tail bleed assays, we found neither Tymp deficiency nor inhibition of TYMP with KIN59 affected coagulation hemostasis or bleeding. These data suggest that regulation of TYMP expression or activity is safe and may achieve therapeutic effects.
In summary, our study demonstrated for the first time that TYMP participates in platelet signaling and plays an important role in regulating platelet activation. Genetic deletion of TYMP or pharmacological inhibition of TYMP activity dramatically inhibited platelet activation in vitro and significantly prolonged thrombosis time in vivo. We conclude that pharmacological inhibition of TYMP activity might be a novel approach to develop antiplatelet and antithrombotic therapy.
